Prime Medicine (PRME) EBITDA (2021 - 2026)

Prime Medicine (PRME) has 6 years of EBITDA data on file, last reported at -$49.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 5.2% year-over-year to -$49.2 million; the trailing twelve-month figure through Mar 2026 stood at -$198.4 million (up 1.77% YoY), and the FY2025 full-year result was -$201.1 million, down 2.65% from the prior year.
• EBITDA for Q1 2026 stood at -$49.2 million, down from -$46.0 million in the prior quarter.
• Across five years, EBITDA topped out at -$23.8 million in Q1 2022 and bottomed at -$65.5 million in Q4 2023.
• The 5-year median for EBITDA is -$46.0 million (2025), against an average of -$45.1 million.
• Peak annual rise in EBITDA reached 37.69% in 2022, while the deepest fall reached 80.96% in 2022.
• A 5-year view of EBITDA shows it stood at -$39.2 million in 2022, then tumbled by 67.06% to -$65.5 million in 2023, then surged by 35.43% to -$42.3 million in 2024, then declined by 8.83% to -$46.0 million in 2025, then slipped by 6.9% to -$49.2 million in 2026.
• The last three EBITDA figures came in at -$49.2 million (Q1 2026), -$46.0 million (Q4 2025), and -$50.5 million (Q3 2025), per Business Quant data.

Peer Comparison